Entering text into the input field will update the search result below

Bristol-Myers Squibb's Multiple Myeloma Setback, And Other News: The Good, Bad And Ugly Of Biopharma


  • Xenon pharma reported financial results.
  • Myovant moves forward with relugolix.
  • BMY suffers a setback with its MM drug.
  • Looking for more stock ideas like this one? Get them exclusively at The Total Pharma Tracker. Get started today »

Xenon Pharmaceuticals Reports Financial Results, Misses EPS

Xenon Pharmaceuticals (XENE) reported its fourth quarter and full-year results. While the results were largely impressive, the company missed reaching its revenue and EPS estimates. The company also provided corporate updates about its various activities. For its full year, the company's revenue was at $6.8 million, in comparison to nil revenue it had reported in the year earlier.

Xenon reported spending $38.8 million on its research and development activities during the entire year while it had registered $23.6 million in research and development expenses for the previous year. The general and administrative expenses for the entire year stood at $10.8 million in comparison to $8.4 million it had spent in the previous year. Xenon reported its other operating expenses at nil while its other incomes for the entire year were at $1.2 million.

Xenon reported that Flexion Therapeutics Inc. (FLXN) has acquired the global rights for developing and commercializing XEN402, which is now known as FX301. Dr. Simon Pimstone, Xenon's Chief Executive Officer, said:

We are focused on developing multiple innovative products for the treatment of epilepsy and believe that Xenon has one of the most exciting epilepsy pipelines currently in development."

The company also provided updates about its ongoing collaboration with Neurocrine Biosciences Inc. (NBIX) for developing treatments for epilepsy.

Xenon is a clinical-stage biopharmaceutical company and is mainly engaged in developing and commercializing treatments for neurological disorders. Its lead drug candidate XEN1101 is a differentiated Kv7 potassium channel modulator for treating epilepsy while its XEN496, a Kv7 potassium channel modulator has been given orphan drug designation for treating KCNQ2 developmental and epileptic encephalopathy. The company filed an Investigational New Drug application pertaining a pharmacokinetic study testing proprietary pediatric formulation of ezogabine (XEN496) in healthy adult volunteers.

Myovant Sciences Goes Ahead with

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

This article was written by

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

GreenPirate profile picture
We bought MYOV early on, and remain hopeful. Analysts at JMP and Leerink Partners are hopeful too. Hopefully, Myovant's estrogen and progesterone suppressant, Relugolix, will continue to increase sales.

The company web site reports: "We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF)."

A lot going on.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About BMY

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMY

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.